{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:40:33Z","timestamp":1781534433743,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"No funding for this study"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that often requires biological therapy to control its activity. Medication persistence and adherence are important aspects on which we have scarce information. We performed a longitudinal, retrospective, and observational study based on data from the daily clinical management of JIA patients. We recorded clinical remission at 6 and 12\u00a0months. Persistence of biological therapy was evaluated using Kaplan\u2013Meier curves, and adherence was assessed using the medication possession ratio (MPR). We included 68 patients who received biological therapy. Of these, 11 (16.2%) and 5 (7.4%) required a second and third drug, respectively. The persistence rate for biological therapy at 5\u00a0years was 64%, with no differences between the first and second lines. Adherence was high during the first year of treatment (MPR80: 96.3%) and also in the second and third years (MPR80: 85.2% and 91.8%, respectively). Persistence and adherence to biological therapy were remarkably high in our JIA cohort. Adherence to biological treatments could be related to a higher probability of fulfilling the Wallace remission criteria at 6\u00a0months, although this was not confirmed at 12\u00a0months.<\/jats:p>","DOI":"10.1038\/s41598-021-95252-8","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:03:10Z","timestamp":1628589790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Persistence and adherence to biologic therapies in juvenile idiopathic arthritis"],"prefix":"10.1038","volume":"11","author":[{"given":"Juan Carlos","family":"Nieto-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Trives-Folguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Melgarejo-Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Ais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Serrano-Benavente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Sanjurjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"\u00c1lvaro-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indalecio Monteagudo","family":"S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"95252_CR1","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty, R. E. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: Second Revision, Edmonton 2001. J. Rheumatol. 31, 390\u2013392 (2004).","journal-title":"J. Rheumatol."},{"key":"95252_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman, T. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken) 63, 465\u2013482 (2011).","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"95252_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","volume":"326","author":"EH Giannini","year":"1992","unstructured":"Giannini, E. H. et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children\u2019s Study Group. N. Engl. J. Med. 326, 1043\u20131049 (1992).","journal-title":"N. Engl. J. Med."},{"key":"95252_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell, D. J. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342, 763\u2013769 (2000).","journal-title":"N. Engl. J. Med."},{"key":"95252_CR5","doi-asserted-by":"crossref","unstructured":"Lovell, D.J., Ruperto, N., Goodman, S., Reiff, A., Jung, L., Jarosova, K. et al.; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359, 810\u2013820 (2008).","DOI":"10.1056\/NEJMoa0706290"},{"key":"95252_CR6","doi-asserted-by":"crossref","unstructured":"Kearsley-Fleet, L., Heaf, E., Davies, R., Baildam, E., Beresford, M.W., Foster, H.E. et al.; BCRD and BSPAR-ETN study groups. Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. Lancet Rheumatol. 2, e217\u2013e226 (2020).","DOI":"10.1016\/S2665-9913(20)30025-4"},{"key":"95252_CR7","unstructured":"Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J. Rheumatol. 31, 2290\u20132294 (2004)."},{"key":"95252_CR8","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace, C. A. et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 64, 2012\u20132021 (2012).","journal-title":"Arthritis Rheum."},{"key":"95252_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","volume":"79","author":"A Klein","year":"2020","unstructured":"Klein, A., Minden, K., Hospach, A., Foeldvari, I., Weller-Heinemann, F., Trauzeddel, R. et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 79, 969\u2013974 (2020).","journal-title":"Ann Rheum Dis."},{"key":"95252_CR10","first-page":"819","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli, A. et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 77, 819\u2013828 (2018).","journal-title":"Ann Rheum Dis."},{"key":"95252_CR11","doi-asserted-by":"crossref","unstructured":"Adherence to Long-term Therapies: Evidence for Action, WHO 2003. IBSN 92 4 154599 2.","DOI":"10.1016\/S1474-5151(03)00091-4"},{"key":"95252_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","volume":"18","author":"G Horneff","year":"2016","unstructured":"Horneff, G. et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res. Ther. 18, 272 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"95252_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13075-018-1728-3","volume":"20","author":"JJ Bethencourt Baute","year":"2018","unstructured":"Bethencourt Baute, J. J. et al. Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBASADER. Arthritis Res. Ther. 20, 227 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"95252_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.4081\/reumatismo.2013.682","volume":"65","author":"M Romano","year":"2013","unstructured":"Romano, M. et al. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Reumatismo 65, 278\u2013295 (2013).","journal-title":"Reumatismo"},{"key":"95252_CR15","doi-asserted-by":"crossref","unstructured":"Kearley-Fleet, L., Vicente Gonz\u00e1lez, L., Steinke, D. et al. Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. Rheumatology (2019).","DOI":"10.1093\/rheumatology\/kez048"},{"key":"95252_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/rheumatology\/kev398","volume":"55","author":"A Mourao","year":"2016","unstructured":"Mourao, A. et al. Effectiveness and long-term retention of anti-tumour necrosis factor treatment in juvenile and adult patients with juvenile idiopathic arthritis: data from Reuma.pt. Rheumatology 55, 697\u2013703 (2016).","journal-title":"Rheumatology"},{"key":"95252_CR17","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s10067-017-3712-8","volume":"36","author":"EG Favalli","year":"2017","unstructured":"Favalli, E. G. et al. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritis in adult- and juvenile-onset populations: similarities and differences. Clin. Rheumatol. 36, 1747\u20131755 (2017).","journal-title":"Clin. Rheumatol."},{"key":"95252_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3899\/jrheum.120753","volume":"40","author":"S Ringold","year":"2013","unstructured":"Ringold, S., Grant, S., Girdish, C., Vallace, C. & Sullivan, S. Methotrexate and injectable tumor necrosis factor-alpha inhibitor adherence and persistence in children with rheumatic diseases. J. Rheumatol. 40, 80\u201386 (2013).","journal-title":"J. Rheumatol."},{"key":"95252_CR19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.semarthrit.2017.05.007","volume":"47","author":"SJW Shoop-Worrall","year":"2017","unstructured":"Shoop-Worrall, S. J. W., Kearsley-Fleet, L., Thomson, W., Verstappen, S. M. M. & Hyrich, K. L. How common is remission in juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum. 47, 331\u2013337 (2017).","journal-title":"Semin Arthritis Rheum."},{"key":"95252_CR20","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3899\/jrheum.171087","volume":"45","author":"LA Favier","year":"2018","unstructured":"Favier, L. A. et al. Barriers to adherence in juvenile idiopathic arthritis: A multicenter collaborative experience and preliminary results. J Rheumatol. 45, 690\u2013696 (2018).","journal-title":"J Rheumatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95252-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95252-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95252-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:14:49Z","timestamp":1670069689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-95252-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["95252"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-95252-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"25 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16195"}}